---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-24-000109"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:37:48.118701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q3 product revenue $6.0M, net loss narrows; ANKTIVA J-code set for Jan 2025

## Summary
- Net product revenue of $6.0M from ANKTIVA launch in Q3, up from $1.0M in Q2; diluted EPS -$0.14 vs -$0.19 YoY.
- Permanent J-code for ANKTIVA issued, effective Jan 1, 2025; medical coverage for over 200M lives secured.
- MAA submitted to UK MHRA for ANKTIVA; EU submission planned in Q4 2024, covering 30 countries.
- Cash and marketable securities $130.4M as of Sept 30; net loss attributable to stockholders -$85.7M vs -$95.6M YoY.
- ANKTIVA shelf life extended to 3 years; over 125,000 doses available for market and trials.

## SEC filing metadata
- accession: 0001326110-24-000109
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611024000109/0001326110-24-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611024000109/ibrx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-24-000109
- JSON: https://secwatch.observer/filing/0001326110-24-000109.json
- Plain text: https://secwatch.observer/filing/0001326110-24-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.